Pretzel Therapeutics launches with $72M for Mitochondrial Therapies
Pretzel Therapeutics, a biotech startup company, launched its Series A financing on Monday. The funding will be used to develop novel mitochondria-based treatments for genetic disorders that are rare and diseases associated with aging.
Pretzel’s plan is to focus on mitochondrial diseases. These are a group of highly heterogeneous conditions that can be caused by DNA mutations within the mitochondria or nucleus. These diseases are extremely rare and affect one person in every 5,000.
Pretzel CEO Jay Parrish said to BioSpace that the funding \”should allow us to get near the clinic, if not in the clinic, with one or more of our programs.\”